yaaY Antibody

What is YAP1 and why is it a significant research target?

YAP1 (Yes-associated protein 1) is a 65kDa protein encoded by the YAP1 gene and serves as a transcriptional regulator in the Hippo signaling pathway. With an observed molecular weight of 65-75 kDa, this protein is critical in research because it influences cell proliferation, apoptosis, and organ size control. YAP1 has been implicated in various cancers and developmental processes, making antibodies against it valuable tools for understanding disease mechanisms .

How should researchers validate a YAP1 antibody before experimental use?

Proper validation requires demonstrating that the antibody: 1) binds to the target YAP1 protein, 2) binds to YAP1 when present in complex protein mixtures, 3) does not bind to proteins other than YAP1, and 4) performs as expected under specific experimental conditions. The most rigorous validation approach involves testing the antibody in knockout (KO) cell lines, which has been shown to be superior to other control methods, particularly for Western blots and immunofluorescence imaging . For YAP1 specifically, validation data should include positive detection in tissues and cell lines where expression is expected, such as HeLa cells, HepG2 cells, and liver tissues .

What are the recommended applications and dilutions for YAP1 antibody use?

YAP1 antibody applications include Western blot, immunoprecipitation, immunohistochemistry, and immunofluorescence. Based on published validation data, the following dilutions are recommended:

Each application requires optimization for specific experimental conditions .

How does the performance of different types of YAP1 antibodies compare?

Recent large-scale antibody characterization studies have revealed that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies across standard assays. For YAP1 specifically, performance varies by antibody class and application. Polyclonal YAP1 antibodies like 13584-1-AP offer broad epitope recognition but may show batch-to-batch variation. For critical quantitative experiments requiring high reproducibility, recombinant YAP1 antibodies are recommended as they combine the consistency of monoclonals with potentially improved affinity .

What controls are essential when using YAP1 antibody in diverse experimental settings?

Controls should be tailored to each application, but knockout controls are considered gold standard. For YAP1 experiments, the following controls are recommended:

• Western blot: Include YAP1 knockout cell lysate alongside wildtype

• Immunofluorescence: Include YAP1 knockout cells processed identically to experimental samples

• Immunoprecipitation: Include IgG-only control and YAP1-depleted lysate

• ChIP assays: Include IgG control and validate with multiple primers

Large-scale studies have shown that approximately 12 publications per protein target included data from antibodies that failed to recognize their target, emphasizing the critical importance of proper controls .

How should researchers address cross-reactivity concerns with YAP1 antibody?

Cross-reactivity should be systematically evaluated through:

• Protein array testing: Determine binding to non-target proteins

• Peptide competition assays: Confirm specificity to YAP1 epitopes

• Multi-species testing: Verify expected cross-reactivity with orthologs

• Isoform analysis: Determine which YAP1 isoforms are recognized

For YAP1 specifically, researchers should note that the antibody may detect multiple bands due to post-translational modifications and isoforms. The calculated molecular weight is 54 kDa, but observed weights typically range from 65-75 kDa .

What are common challenges when using YAP1 antibody and how can they be addressed?

Researchers frequently encounter several issues when working with YAP1 antibodies:

• Variable signal intensity: Optimize protein loading (10-30 μg for Western blot) and incubation conditions (overnight at 4°C often improves sensitivity)

• Background in immunostaining: Test different blocking agents (5% BSA vs. normal serum) and increase washing steps

• Nuclear vs. cytoplasmic localization discrepancies: Use fractionation controls to verify compartment-specific signals

• Inconsistent band patterns: Compare results with literature and verify with knockout controls

Recent antibody characterization efforts have shown that approximately 50% of commercial antibodies fail to meet basic characterization standards, so thorough validation is essential to avoid unreliable results .

How can researchers determine if contradictory YAP1 antibody results reflect biology or technical artifacts?

When faced with contradictory results:

• Compare antibody epitopes: Different antibodies may recognize distinct domains affected by protein interactions or modifications

• Analyze experimental conditions: YAP1 localization and activity are highly dependent on cell density, serum conditions, and mechanical cues

• Verify with orthogonal methods: Combine antibody-based detection with mass spectrometry or CRISPR-based tagging

• Test multiple antibodies: Use antibodies recognizing different epitopes to distinguish technical from biological variation

The YCharOS initiative found that an average of 12 publications per protein target included data from antibodies that failed to recognize their target, highlighting the importance of rigorous validation .

What information should researchers include in publications to ensure YAP1 antibody experiments are reproducible?

To ensure reproducibility, publications should include:

• Complete antibody identification: Catalog number, lot number, RRID (e.g., AB_2218915 for YAP1 antibody 13584-1-AP)

• Validation evidence: Reference to or inclusion of knockout/knockdown controls

• Detailed protocols: Complete methods including blocking conditions, antibody dilutions, incubation times/temperatures

• Image acquisition parameters: Exposure settings, gain, and post-processing details

• Quantification methods: Software, regions of interest selection criteria, and normalization approach

Inadequate antibody characterization is estimated to result in financial losses of $0.4-1.8 billion per year in the United States alone due to irreproducible research .

How do current antibody characterization initiatives impact YAP1 research?

Several initiatives are improving antibody reliability:

• YCharOS: Tests antibodies in knockout cell lines for Western blot, immunoprecipitation, and immunofluorescence, having evaluated over 1,000 antibodies with published reports

• Antibody Registry: Assigns unique RRIDs to antibodies, such as RRID:AB_2218915 for YAP1 antibody

• Consensus protocols: A collaboration between YCharOS and antibody manufacturers has established standardized protocols for antibody validation

These efforts have revealed that commercial catalogs contain specific and renewable antibodies for more than half of the human proteome, but also that many published studies use antibodies that fail validation tests .

How are YAP1 antibodies being used in advanced cancer research methodologies?

YAP1 antibodies are central to several cutting-edge cancer research applications:

• Spatial transcriptomics: Combining YAP1 immunofluorescence with RNA-seq to correlate localization with gene expression

• Patient-derived xenograft models: Evaluating YAP1 expression and localization as biomarkers for treatment response

• Drug discovery screens: Identifying compounds that modulate YAP1 nuclear localization or protein interactions

• Liquid biopsy development: Detecting YAP1 in circulating tumor cells as potential diagnostic markers

Publications using YAP1 antibodies span multiple cancer types, with particular focus on liver, ovarian, colon, and lung cancers .

What developments in antibody technology are enhancing YAP1 research capabilities?

Recent technological advances include:

• Recombinant antibody production: Creating more consistent reagents with defined sequences

• Miniaturized antibody formats: Developing single-domain antibodies for improved tissue penetration

• Multiplexed detection systems: Combining YAP1 with other markers in single samples

• Live-cell compatible antibody fragments: Allowing real-time tracking of YAP1 dynamics

Studies have shown that recombinant antibodies outperform traditional monoclonal and polyclonal antibodies in standard assays, suggesting a transition toward these more reliable reagents .